Cantargia AB (publ) (CANTA.ST)
- Previous Close
1.6380 - Open
1.6400 - Bid 1.6000 x --
- Ask 1.6060 x --
- Day's Range
1.5900 - 1.6500 - 52 Week Range
1.1420 - 5.2000 - Volume
179,918 - Avg. Volume
970,472 - Market Cap (intraday)
399.271M - Beta (5Y Monthly) 1.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8800 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.85
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
cantargia.comRecent News: CANTA.ST
View MorePerformance Overview: CANTA.ST
Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CANTA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CANTA.ST
View MoreValuation Measures
Market Cap
407.23M
Enterprise Value
374.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.43%
Return on Equity (ttm)
-113.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-161.65M
Diluted EPS (ttm)
-0.8800
Balance Sheet and Cash Flow
Total Cash (mrq)
33.04M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-211.42M